TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer types

Abstract Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the current panels for next generation sequencing (NGS) of tumor samples are focused on drivers and actionable genes and give inaccurate predictions of TMB. TMBpred provides an easy to use web server for the selection of NGSs panels and models that can offer reliable and clinically relevant estimates of TMBs for 14 human malignancies. It also gives a TMB prediction based on preexisting sequencing data, which can be of help to improve the selection of patients that will benefit from the ICB therapy. The best panels provided by our server have between 0.23 and 1.49 Mb, in range with the panels currently used in clinical labs.